Integrins in cancer: biological implications and therapeutic opportunities (original) (raw)

• Mitra, S. K. & Schlaepfer, D. D. Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr. Opin. Cell Biol. 18, 516–523 (2006).
  Article CAS PubMed Google Scholar
• Guo, W. & Giancotti, F. G. Integrin signalling during tumour progression. Nature Rev. Mol. Cell Biol. 5, 816–826 (2004).
  Article CAS Google Scholar
• Assoian, R. K. & Klein, E. A. Growth control by intracellular tension and extracellular stiffness. Trends Cell Biol. 18, 347–352 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Han, S., Khuri, F. R. & Roman, J. Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways. Cancer Res. 66, 315–323 (2006).
  Article CAS PubMed Google Scholar
• Vellon, L., Menendez, J. A. & Lupu, R. αVβ3 integrin regulates heregulin (HRG)-induced cell proliferation and survival in breast cancer. Oncogene 24, 3759–3773 (2005).
  Article CAS PubMed Google Scholar
• Pytela, R., Pierschbacher, M. D. & Ruoslahti, E. Identification and isolation of a 140 kd cell surface glycoprotein with properties expected of a fibronectin receptor. Cell 40, 191–198 (1985). This seminal work provides the first description of an RGD-mediated cell adhesion mechanism.
  Article CAS PubMed Google Scholar
• Berrier, A. L. & Yamada, K. M. Cell-matrix adhesion. J. Cell Physiol. 213, 565–573 (2007).
  Article CAS PubMed Google Scholar
• Legate, K. R., Montanez, E., Kudlacek, O. & Fassler, R. ILK, PINCH and parvin: the tIPP of integrin signalling. Nature Rev. Mol. Cell Biol. 7, 20–31 (2006).
  Article CAS Google Scholar
• Zoller, M. Tetraspanins: push and pull in suppressing and promoting metastasis. Nature Rev. Cancer 9, 40–55 (2009).
  Article CAS Google Scholar
• Han, J. et al. Reconstructing and deconstructing agonist-induced activation of integrin αIIbβ3. Curr. Biol. 16, 1796–1806 (2006).
  Article CAS PubMed Google Scholar
• Kren, A. et al. Increased tumor cell dissemination and cellular senescence in the absence of β1-integrin function. EMBO J. 26, 2832–2842 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Zutter, M. M., Santoro, S. A., Staatz, W. D. & Tsung, Y. L. Re-expression of the alpha 2 beta 1 integrin abrogates the malignant phenotype of breast carcinoma cells. Proc. Natl Acad. Sci. USA 92, 7411–7415 (1995).
  Article CAS PubMed PubMed Central Google Scholar
• Matter, M. L. & Ruoslahti, E. A signaling pathway from the α5β1 and αvβ3 integrins that elevates bcl-2 transcription. J. Biol. Chem. 276, 27757–27763 (2001).
  Article CAS PubMed Google Scholar
• Uhm, J. H., Dooley, N. P., Kyritsis, A. P., Rao, J. S. & Gladson, C. L. Vitronectin, a glioma-derived extracellular matrix protein, protects tumor cells from apoptotic death. Clin. Cancer Res. 5, 1587–1594 (1999).
  CAS PubMed Google Scholar
• Aoudjit, F. & Vuori, K. Matrix attachment regulates Fas-induced apoptosis in endothelial cells: a role for c-flip and implications for anoikis. J. Cell Biol. 152, 633–643 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Aoudjit, F. & Vuori, K. Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells. Oncogene 20, 4995–5004 (2001).
  Article CAS PubMed Google Scholar
• Scatena, M. et al. NF-κB mediates αvβ3 integrin-induced endothelial cell survival. J. Cell Biol. 141, 1083–1093 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Courter, D. L., Lomas, L., Scatena, M. & Giachelli, C. M. Src kinase activity is required for integrin αVβ3-mediated activation of nuclear factor-κB. J. Biol. Chem. 280, 12145–12151 (2005).
  Article CAS PubMed Google Scholar
• Bao, W. & Stromblad, S. Integrin αv-mediated inactivation of p53 controls a MEK1-dependent melanoma cell survival pathway in three-dimensional collagen. J. Cell Biol. 167, 745–756 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Hood, J. D., Frausto, R., Kiosses, W. B., Schwartz, M. A. & Cheresh, D. A. Differential αv integrin-mediated Ras-ERK signaling during two pathways of angiogenesis. J. Cell Biol. 162, 933–943 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Alavi, A., Hood, J. D., Frausto, R., Stupack, D. G. & Cheresh, D. A. Role of Raf in vascular protection from distinct apoptotic stimuli. Science 301, 94–96 (2003). This paper identifies a central role for Raf in protecting endothelial cells from distinct mediators of apoptosis.
  Article CAS PubMed Google Scholar
• Reynolds, L. E. et al. Enhanced pathological angiogenesis in mice lacking β3 integrin or β3 and β5 integrins. Nature Med. 8, 27–34 (2002). This paper demonstrates that the genetic deletion of Itgb3 in mice failed to inhibit, and actually potentiated, angiogenesis.
  Article CAS PubMed Google Scholar
• Reynolds, A. R. et al. Elevated Flk1 (vascular endothelial growth factor receptor 2) signaling mediates enhanced angiogenesis in β3-integrin-deficient mice. Cancer Res. 64, 8643–8650 (2004).
  Article CAS PubMed Google Scholar
• Weis, S. M. et al. Cooperation between VEGF and β3 integrin during cardiac vascular development. Blood 109, 1962–1970 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Petitclerc, E. et al. Integrin αvβ3 promotes M21 melanoma growth in human skin by regulating tumor cell survival. Cancer Res. 59, 2724–2730 (1999).
  CAS PubMed Google Scholar
• Varner, J. A., Emerson, D. A. & Juliano, R. L. Integrin alpha 5 beta 1 expression negatively regulates cell growth: reversal by attachment to fibronectin. Mol. Biol. Cell 6, 725–740 (1995).
  Article CAS PubMed PubMed Central Google Scholar
• Giancotti, F. G. & Ruoslahti, E. Elevated levels of the α5 β1 fibronectin receptor suppress the transformed phenotype of Chinese hamster ovary cells. Cell 60, 849–859 (1990). This study shows that in addition to their pro-tumorigenic effects, integrins can suppress transformation under some conditions.
  Article CAS PubMed Google Scholar
• Kanamori, M., Vanden Berg, S. R., Bergers, G., Berger, M. S. & Pieper, R. O. Integrin β3 overexpression suppresses tumor growth in a human model of gliomagenesis: implications for the role of β3 overexpression in glioblastoma multiforme. Cancer Res. 64, 2751–2758 (2004).
  Article CAS PubMed Google Scholar
• Danen, E. H., van Kraats, A. A., Cornelissen, I. M., Ruiter, D. J. & van Muijen, G. N. Integrin β3 cDNA transfection into a highly metastatic αv β3-negative human melanoma cell line inhibits invasion and experimental metastasis. Biochem. Biophys. Res. Commun. 226, 75–81 (1996).
  Article CAS PubMed Google Scholar
• Stupack, D. G., Puente, X. S., Boutsaboualoy, S., Storgard, C. M. & Cheresh, D. A. Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins. J. Cell Biol. 155, 459–470 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Zhao, H., Ross, F. P. & Teitelbaum, S. L. Unoccupied αvβ3 integrin regulates osteoclast apoptosis by transmitting a positive death signal. Mol. Endocrinol. 19, 771–780 (2005).
  Article CAS PubMed Google Scholar
• Frisch, S. M. & Screaton, R. A. Anoikis mechanisms. Curr. Opin. Cell Biol. 13, 555–562 (2001).
  Article CAS PubMed Google Scholar
• Stupack, D. G. et al. Potentiation of neuroblastoma metastasis by loss of caspase-8. Nature 439, 95–99 (2006). This paper demonstrates that tumour invasion and metastasis occurs following resistance to IMD owing to the loss of caspase 8.
  Article CAS PubMed Google Scholar
• Desgrosellier, J. S., et al. Integrin αvβ3-c-Src oncogenic unit promotes anchorage-independence and tumor progression. Nature Med. 15, 1163–1169 (2009). This paper describes a role for unligated integrin αvβ3 in increasing anchorage-independent survival and metastasis through an integrin αvβ3–SRC signalling module.
  Article CAS PubMed Google Scholar
• Albelda, S. M. et al. Integrin distribution in malignant melanoma: association of the β3 subunit with tumor progression. Cancer Res. 50, 6757–6764 (1990).
  CAS PubMed Google Scholar
• Takayama, S. et al. The relationship between bone metastasis from human breast cancer and integrin αvβ3 expression. Anticancer Res. 25, 79–83 (2005).
  CAS PubMed Google Scholar
• Liapis, H., Flath, A. & Kitazawa, S. Integrin αVβ3 expression by bone-residing breast cancer metastases. Diagn. Mol. Pathol. 5, 127–135 (1996).
  Article CAS PubMed Google Scholar
• Sloan, E. K. et al. Tumor-specific expression of αvβ3 integrin promotes spontaneous metastasis of breast cancer to bone. Breast Cancer Res. 8, R20 (2006).
  Article PubMed PubMed Central CAS Google Scholar
• McCabe, N. P., De, S., Vasanji, A., Brainard, J. & Byzova, T. V. Prostate cancer specific integrin αvβ3 modulates bone metastatic growth and tissue remodeling. Oncogene 26, 6238–6243 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Hosotani, R. et al. Expression of integrin αvβ3 in pancreatic carcinoma: relation to MMP-2 activation and lymph node metastasis. Pancreas 25, e30–35 (2002).
  Article PubMed Google Scholar
• Gruber, G. et al. Correlation between the tumoral expression of β3-integrin and outcome in cervical cancer patients who had undergone radiotherapy. Br. J. Cancer 92, 41–46 (2005).
  Article CAS PubMed Google Scholar
• Asselin-Labat, M. L. et al. Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation. Nature Cell Biol. 9, 201–209 (2007).
  Article CAS PubMed Google Scholar
• Vaillant, F. et al. The mammary progenitor marker CD61/β3 integrin identifies cancer stem cells in mouse models of mammary tumorigenesis. Cancer Res. 68, 7711–7717 (2008).
  Article CAS PubMed Google Scholar
• Taverna, D., Crowley, D., Connolly, M., Bronson, R. T. & Hynes, R. O. A direct test of potential roles for β3 and β5 integrins in growth and metastasis of murine mammary carcinomas. Cancer Res. 65, 10324–10329 (2005).
  Article CAS PubMed Google Scholar
• Luo, M. et al. Mammary epithelial-specific ablation of the focal adhesion kinase suppresses mammary tumorigenesis by affecting mammary cancer stem/progenitor cells. Cancer Res. 69, 466–474 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Samanna, V., Wei, H., Ego-Osuala, D. & Chellaiah, M. A. Alpha-V-dependent outside-in signaling is required for the regulation of CD44 surface expression, MMP-2 secretion, and cell migration by osteopontin in human melanoma cells. Exp. Cell Res. 312, 2214–2230 (2006).
  Article CAS PubMed Google Scholar
• Avraamides, C. J., Garmy-Susini, B. & Varner, J. A. Integrins in angiogenesis and lymphangiogenesis. Nature Rev. Cancer 8, 604–617 (2008).
  Article CAS Google Scholar
• Ribatti, D. The contribution of Harold F. Dvorak to the study of tumor angiogenesis and stroma generation mechanisms. Endothelium 14, 131–135 (2007).
  Article CAS PubMed Google Scholar
• Brooks, P. C., Clark, R. A. & Cheresh, D. A. Requirement of vascular integrin αvβ3 for angiogenesis. Science 264, 569–571 (1994). This paper provides the first demonstration that an antagonist to integrin αvβ3 blocks angiogenesis.
  Article CAS PubMed Google Scholar
• Davis, G. E. Affinity of integrins for damaged extracellular matrix: αvβ3 binds to denatured collagen type I through RGD sites. Biochem. Biophys. Res. Commun. 182, 1025–1031 (1992).
  Article CAS PubMed Google Scholar
• Friedlander, M. et al. Definition of two angiogenic pathways by distinct αv integrins. Science 270, 1500–1502 (1995). This paper defines two distinct pathways of angiogenesis that require specific integrin–growth factor receptor pairs.
  Article CAS PubMed Google Scholar
• Baluk, P., Hashizume, H. & McDonald, D. M. Cellular abnormalities of blood vessels as targets in cancer. Curr. Opin. Genet. Dev. 15, 102–111 (2005).
  Article CAS PubMed Google Scholar
• Garmy-Susini, B. et al. Integrin α4β1-VCAM-1-mediated adhesion between endothelial and mural cells is required for blood vessel maturation. J. Clin. Invest. 115, 1542–1551 (2005). This paper describes the importance of integrin-mediated interactions between endothelial cells and pericytes for vascular maturation.
  Article CAS PubMed PubMed Central Google Scholar
• Fukumura, D. & Jain, R. K. Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. Microvasc. Res. 74, 72–84 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Greenberg, J. I. et al. A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature 456, 809–813 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Conti, J. A. et al. The desmoplastic reaction surrounding hepatic colorectal adenocarcinoma metastases aids tumor growth and survival via αv integrin ligation. Clin. Cancer Res. 14, 6405–6413 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Zhu, C. Q. et al. Integrin α11 regulates IGF2 expression in fibroblasts to enhance tumorigenicity of human non-small-cell lung cancer cells. Proc. Natl Acad. Sci. USA 104, 11754–11759 (2007). This paper demonstrates a crucial role for integrin α11β1 that is expressed on tumour-associated fibroblasts in tumour progression.
  Article CAS PubMed PubMed Central Google Scholar
• Taverna, D. et al. Increased primary tumor growth in mice null for β3- or β3/β5-integrins or selectins. Proc. Natl Acad. Sci. USA 101, 763–768 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Feng, W. et al. The angiogenic response is dictated by β3 integrin on bone marrow-derived cells. J. Cell Biol. 183, 1145–1157 (2008). This paper describes the novel observation that integrin αvβ3 expression on bone marrow-derived cells is crucial for angiogenesis that occurs during wound healing and tumour growth.
  Article CAS PubMed PubMed Central Google Scholar
• Jin, H. et al. A homing mechanism for bone marrow-derived progenitor cell recruitment to the neovasculature. J. Clin. Invest. 116, 652–662 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Jin, H., Su, J., Garmy-Susini, B., Kleeman, J. & Varner, J. Integrin α4β1 promotes monocyte trafficking and angiogenesis in tumors. Cancer Res. 66, 2146–2152 (2006).
  Article CAS PubMed Google Scholar
• Bakewell, S. J. et al. Platelet and osteoclast β3 integrins are critical for bone metastasis. Proc. Natl Acad. Sci. USA 100, 14205–14210 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Felding-Habermann, B., Habermann, R., Saldivar, E. & Ruggeri, Z. M. Role of β3 integrins in melanoma cell adhesion to activated platelets under flow. J. Biol. Chem. 271, 5892–5900 (1996).
  Article CAS PubMed Google Scholar
• Felding-Habermann, B. et al. Integrin activation controls metastasis in human breast cancer. Proc. Natl Acad. Sci. USA 98, 1853–1858 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Trikha, M. et al. Multiple roles for platelet GPIIb/IIIa and αvβ3 integrins in tumor growth, angiogenesis, and metastasis. Cancer Res. 62, 2824–2833 (2002).
  CAS PubMed Google Scholar
• Guo, W. et al. β4 integrin amplifies ErbB2 signaling to promote mammary tumorigenesis. Cell 126, 489–502 (2006). This paper provides the first demonstration that oncogenes may cooperate with integrins to initiate tumorigenesis.
  Article CAS PubMed Google Scholar
• White, D. E. et al. Targeted disruption of β1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction. Cancer Cell 6, 159–170 (2004).
  Article CAS PubMed Google Scholar
• Macias-Perez, I. et al. Loss of integrin α1β1 ameliorates Kras-induced lung cancer. Cancer Res. 68, 6127–6135 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Lahlou, H. et al. Mammary epithelial-specific disruption of the focal adhesion kinase blocks mammary tumor progression. Proc. Natl Acad. Sci. USA 104, 20302–20307 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Pylayeva, Y. et al. Ras- and PI3K-dependent breast tumorigenesis in mice and humans requires focal adhesion kinase signaling. J. Clin. Invest. 119, 252–266 (2009).
  CAS PubMed PubMed Central Google Scholar
• Huveneers, S. et al. Integrin αvβ3 controls activity and oncogenic potential of primed c-Src. Cancer Res. 67, 2693–2700 (2007).
  Article CAS PubMed Google Scholar
• Huveneers, S., Arslan, S., van de Water, B., Sonnenberg, A. & Danen, E. H. Integrins uncouple Src-induced morphological and oncogenic transformation. J. Biol. Chem. 283, 13243–13251 (2008).
  Article CAS PubMed Google Scholar
• Shimizu, H., Seiki, T., Asada, M., Yoshimatsu, K. & Koyama, N. α6β1 integrin induces proteasome-mediated cleavage of erbB2 in breast cancer cells. Oncogene 22, 831–839 (2003).
  Article CAS PubMed Google Scholar
• Borges, E., Jan, Y. & Ruoslahti, E. Platelet-derived growth factor receptor β and vascular endothelial growth factor receptor 2 bind to the β3 integrin through its extracellular domain. J. Biol. Chem. 275, 39867–39873 (2000).
  Article CAS PubMed Google Scholar
• Schneller, M., Vuori, K. & Ruoslahti, E. αvβ3 integrin associates with activated insulin and PDGFβ receptors and potentiates the biological activity of PDGF. EMBO J. 16, 5600–5607 (1997).
  Article CAS PubMed PubMed Central Google Scholar
• Soldi, R. et al. Role of αvβ3 integrin in the activation of vascular endothelial growth factor receptor-2. EMBO J. 18, 882–892 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Trusolino, L., Bertotti, A. & Comoglio, P. M. A signaling adapter function for α6β4 integrin in the control of HGF-dependent invasive growth. Cell 107, 643–654 (2001). This paper identifies a crucial crosstalk mechanism between integrin α6β4 and MET that increases HGF-induced tumour cell invasion.
  Article CAS PubMed Google Scholar
• Miyamoto, S., Teramoto, H., Gutkind, J. S. & Yamada, K. M. Integrins can collaborate with growth factors for phosphorylation of receptor tyrosine kinases and MAP kinase activation: roles of integrin aggregation and occupancy of receptors. J. Cell Biol. 135, 1633–1642 (1996). This paper describes the important collaboration between growth factors and integrins for increased activation of growth factor receptors and potentiation of downstream signalling through MAPK.
  Article CAS PubMed Google Scholar
• Caswell, P. T. et al. Rab-coupling protein coordinates recycling of α5β1 integrin and EGFR1 to promote cell migration in 3D microenvironments. J. Cell Biol. 183, 143–55 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Spangenberg, C. et al. ERBB2-mediated transcriptional up-regulation of the α5β1 integrin fibronectin receptor promotes tumor cell survival under adverse conditions. Cancer Res. 66, 3715–3725 (2006).
  Article CAS PubMed Google Scholar
• Yoon, S. O., Shin, S. & Lipscomb, E. A. A novel mechanism for integrin-mediated ras activation in breast carcinoma cells: the α6β4 integrin regulates ErbB2 translation and transactivates epidermal growth factor receptor/ErbB2 signaling. Cancer Res. 66, 2732–2739 (2006).
  Article CAS PubMed Google Scholar
• Ning, Y., Buranda, T. & Hudson, L. G. Activated epidermal growth factor receptor induces integrin α2 internalization via caveolae/raft-dependent endocytic pathway. J. Biol. Chem. 282, 6380–6387 (2007).
  Article CAS PubMed Google Scholar
• Ning, Y. et al. Down-regulation of integrin α2 surface expression by mutant epidermal growth factor receptor (EGFRvIII) induces aberrant cell spreading and focal adhesion formation. Cancer Res. 65, 9280–9286 (2005).
  Article CAS PubMed Google Scholar
• Ignotz, R. A. & Massague, J. Cell adhesion protein receptors as targets for transforming growth factor-β action. Cell 51, 189–197 (1987).
  Article CAS PubMed Google Scholar
• Wei, Y. Y. et al. Osteoblasts-derived TGF-β1 enhance motility and integrin upregulation through Akt, ERK, and NF-κB-dependent pathway in human breast cancer cells. Mol. Carcinog. 47, 526–537 (2008).
  Article CAS PubMed Google Scholar
• Wang, D. et al. Control of type II transforming growth factor-β receptor expression by integrin ligation. J. Biol. Chem. 274, 12840–12847 (1999).
  Article CAS PubMed Google Scholar
• Engl, T. et al. CXCR4 chemokine receptor mediates prostate tumor cell adhesion through α5 and β3 integrins. Neoplasia 8, 290–301 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Sun, Y. X. et al. Expression and activation of αv β3 integrins by SDF-1/CXC12 increases the aggressiveness of prostate cancer cells. Prostate 67, 61–73 (2007).
  Article CAS PubMed Google Scholar
• Grzesiak, J. J., Smith, K. C., Burton, D. W., Deftos, L. J. & Bouvet, M. Integrin-mediated laminin-1 adhesion upregulates CXCR4 and IL-8 expression in pancreatic cancer cells. Surgery 141, 804–814 (2007).
  Article PubMed Google Scholar
• Wang, S. E. et al. Transforming growth factor beta induces clustering of HER2 and integrins by activating Src-focal adhesion kinase and receptor association to the cytoskeleton. Cancer Res. 69, 475–482 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• De, S. et al. VEGF-integrin interplay controls tumor growth and vascularization. Proc. Natl Acad. Sci. USA 102, 7589–7594 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Klemke, R. L., Yebra, M., Bayna, E. M. & Cheresh, D. A. Receptor tyrosine kinase signaling required for integrin αvβ5-directed cell motility but not adhesion on vitronectin. J. Cell Biol. 127, 859–866 (1994).
  Article CAS PubMed Google Scholar
• Brooks, P. C. et al. Insulin-like growth factor receptor cooperates with integrin αvβ5 to promote tumor cell dissemination in vivo. J. Clin. Invest. 99, 1390–1398 (1997).
  Article CAS PubMed PubMed Central Google Scholar
• Ricono, J. M. et al. Specific cross-talk between epidermal growth factor receptor and integrin αvβ5 promotes carcinoma cell invasion and metastasis. Cancer Res. 69, 1383–1391 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Wayner, E. A., Orlando, R. A. & Cheresh, D. A. Integrins αvβ3 and αvβ5 contribute to cell attachment to vitronectin but differentially distribute on the cell surface. J. Cell Biol. 113, 919–929 (1991).
  Article CAS PubMed Google Scholar
• Pouliot, N., Nice, E. C. & Burgess, A. W. Laminin-10 mediates basal and EGF-stimulated motility of human colon carcinoma cells via α3β1 and α6β4 integrins. Exp. Cell Res. 266, 1–10 (2001).
  Article CAS PubMed Google Scholar
• Yang, C. et al. Integrin α1β1 and α2β1 are the key regulators of hepatocarcinoma cell invasion across the fibrotic matrix microenvironment. Cancer Res. 63, 8312–8317 (2003).
  CAS PubMed Google Scholar
• Moro, L. et al. Integrins induce activation of EGF receptor: role in MAP kinase induction and adhesion-dependent cell survival. EMBO J. 17, 6622–6632 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Moro, L. et al. Integrin-induced epidermal growth factor (EGF) receptor activation requires c-Src and p130Cas and leads to phosphorylation of specific EGF receptor tyrosines. J. Biol. Chem. 277, 9405–9414 (2002).
  Article CAS PubMed Google Scholar
• Bertotti, A., Comoglio, P. M. & Trusolino, L. β4 integrin is a transforming molecule that unleashes Met tyrosine kinase tumorigenesis. Cancer Res. 65, 10674–10679 (2005).
  Article CAS PubMed Google Scholar
• Bertotti, A., Comoglio, P. M. & Trusolino, L. β4 integrin activates a Shp2-Src signaling pathway that sustains HGF-induced anchorage-independent growth. J. Cell Biol. 175, 993–1003 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Chung, J., Yoon, S. O., Lipscomb, E. A. & Mercurio, A. M. The Met receptor and α6β4 integrin can function independently to promote carcinoma invasion. J. Biol. Chem. 279, 32287–32293 (2004).
  Article CAS PubMed Google Scholar
• Crouch, S., Spidel, C. S. & Lindsey, J. S. HGF and ligation of αvβ5 integrin induce a novel, cancer cell-specific gene expression required for cell scattering. Exp. Cell Res. 292, 274–287 (2004).
  Article CAS PubMed Google Scholar
• Sridhar, S. C. & Miranti, C. K. Tetraspanin KAI1/CD82 suppresses invasion by inhibiting integrin-dependent crosstalk with c-Met receptor and Src kinases. Oncogene 25, 2367–2378 (2006).
  Article CAS PubMed Google Scholar
• Munger, J. S. et al. The integrin αvβ6 binds and activates latent TGFβ1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 96, 319–328 (1999).
  Article CAS PubMed Google Scholar
• Ludbrook, S. B., Barry, S. T., Delves, C. J. & Horgan, C. M. The integrin αvβ3 is a receptor for the latency-associated peptides of transforming growth factors β1 and β3. Biochem. J. 369, 311–318 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Marsh, D. et al. αvβ6 Integrin promotes the invasion of morphoeic basal cell carcinoma through stromal modulation. Cancer Res. 68, 3295–3303 (2008).
  Article CAS PubMed Google Scholar
• Van Aarsen, L. A. et al. Antibody-mediated blockade of integrin αvβ6 inhibits tumor progression in vivo by a transforming growth factor-β-regulated mechanism. Cancer Res. 68, 561–570 (2008).
  Article PubMed CAS Google Scholar
• Bates, R. C. et al. Transcriptional activation of integrin β6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma. J. Clin. Invest. 115, 339–347 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Galliher, A. J. & Schiemann, W. P. β3 integrin and Src facilitate transforming growth factor-beta mediated induction of epithelial-mesenchymal transition in mammary epithelial cells. Breast Cancer Res. 8, R42 (2006).
  Article PubMed PubMed Central CAS Google Scholar
• Galliher, A. J. & Schiemann, W. P. Src phosphorylates Tyr284 in TGF-β type II receptor and regulates TGF-β stimulation of p38 MAPK during breast cancer cell proliferation and invasion. Cancer Res. 67, 3752–3758 (2007).
  Article CAS PubMed Google Scholar
• Fransvea, E., Mazzocca, A., Antonaci, S. & Giannelli, G. Targeting transforming growth factor (TGF)-βRI inhibits activation of β1 integrin and blocks vascular invasion in hepatocellular carcinoma. Hepatology 49, 839–850 (2009).
  Article CAS PubMed Google Scholar
• Mahabeleshwar, G. H., Feng, W., Reddy, K., Plow, E. F. & Byzova, T. V. Mechanisms of integrin-vascular endothelial growth factor receptor cross-activation in angiogenesis. Circ. Res. 101, 570–580 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Hood, J. D. et al. Tumor regression by targeted gene delivery to the neovasculature. Science 296, 2404–2407 (2002). This paper demonstrates an essential role for RAF1 in angiogenesis and provides the first demonstration of the effectiveness of integrin-targeted therapeutic delivery to the tumour vasculature.
  Article CAS PubMed Google Scholar
• Byzova, T. V. et al. A mechanism for modulation of cellular responses to VEGF: activation of the integrins. Mol. Cell 6, 851–860 (2000).
  CAS PubMed Google Scholar
• Nikolopoulos, S. N., Blaikie, P., Yoshioka, T., Guo, W. & Giancotti, F. G. Integrin β4 signaling promotes tumor angiogenesis. Cancer Cell 6, 471–483 (2004).
  Article CAS PubMed Google Scholar
• Cardones, A. R., Murakami, T. & Hwang, S. T. CXCR4 enhances adhesion of B16 tumor cells to endothelial cells in vitro and in vivo via β1 integrin. Cancer Res. 63, 6751–6757 (2003).
  CAS PubMed Google Scholar
• Hartmann, T. N., Burger, J. A., Glodek, A., Fujii, N. & Burger, M. CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells. Oncogene 24, 4462–4471 (2005).
  Article CAS PubMed Google Scholar
• Brooks, P. C. et al. Antiintegrin αvβ3 blocks human breast cancer growth and angiogenesis in human skin. J. Clin. Invest. 96, 1815–1822 (1995).
  Article CAS PubMed PubMed Central Google Scholar
• Mulgrew, K. et al. Direct targeting of αvβ3 integrin on tumor cells with a monoclonal antibody, Abegrin. Mol. Cancer Ther. 5, 3122–3129 (2006).
  Article CAS PubMed Google Scholar
• Gramoun, A. et al. Effects of Vitaxin, a novel therapeutic in trial for metastatic bone tumors, on osteoclast functions in vitro. J. Cell Biochem. 102, 341–352 (2007).
  Article CAS PubMed Google Scholar
• Gutheil, J. C. et al. Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin αvβ3. Clin. Cancer Res. 6, 3056–3061 (2000).
  CAS PubMed Google Scholar
• Delbaldo, C. et al. Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against αvβ3 integrin receptor, in patients with advanced solid tumors. Invest. New Drugs 26, 35–43 (2008).
  Article CAS PubMed Google Scholar
• McNeel, D. G. et al. Phase I trial of a monoclonal antibody specific for αvβ3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion. Clin. Cancer Res. 11, 7851–7860 (2005).
  Article CAS PubMed Google Scholar
• Hersey, P. S. et al. A phase II, randomized, open-label study evaluating the antitumor activity of MEDI-522, a humanized monoclonal antibody directed against the human alpha v beta 3 (avb3) integrin, ± dacarbazine (DTIC) in patients with metastatic melanoma (MM). J. Clin. Oncol., 2005 ASCO Annual Meeting Proceedings. Vol. 23, No. 16S, Part I of II (June 1 Supplement), 2005: 7507.
• Trikha, M. et al. CNTO 95, a fully human monoclonal antibody that inhibits αv integrins, has antitumor and antiangiogenic activity in vivo. Int. J. Cancer 110, 326–335 (2004).
  Article CAS PubMed Google Scholar
• Chen, Q. et al. CNTO 95, a fully human anti αv integrin antibody, inhibits cell signaling, migration, invasion, and spontaneous metastasis of human breast cancer cells. Clin. Exp. Metastasis 25, 139–148 (2008).
  Article CAS PubMed Google Scholar
• Martin, P. L. et al. Absence of adverse effects in cynomolgus macaques treated with CNTO 95, a fully human anti-alphav integrin monoclonal antibody, despite widespread tissue binding. Clin. Cancer Res. 11, 6959–6965 (2005).
  Article CAS PubMed Google Scholar
• Mullamitha, S. A. et al. Phase I evaluation of a fully human anti-alphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors. Clin. Cancer Res. 13, 2128–2135 (2007).
  Article CAS PubMed Google Scholar
• Smith, J. W., Ruggeri, Z. M., Kunicki, T. J. & Cheresh, D. A. Interaction of integrins αvβ3 and glycoprotein IIb-IIIa with fibrinogen. Differential peptide recognition accounts for distinct binding sites. J. Biol. Chem. 265, 12267–12271 (1990).
  CAS PubMed Google Scholar
• Beekman, K. W. et al. Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design. Clin. Genitourin Cancer 4, 299–302 (2006).
  Article CAS PubMed Google Scholar
• Nabors, L. B. et al. Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J. Clin. Oncol. 25, 1651–1657 (2007).
  Article CAS PubMed Google Scholar
• MacDonald, T. J. et al. Phase I clinical trial of cilengitide in children with refractory brain tumors: pediatric brain tumor consortium study PBTC-012. J. Clin. Oncol. 26, 919–924 (2008).
  Article CAS PubMed Google Scholar
• Reardon, D. A. et al. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J. Clin. Oncol. 26, 5610–5617 (2008). This study shows the efficacy of cilengitide in a Phase II study of recurrent glioblastoma and provides the basis for the ongoing Phase III trial with this agent.
  Article CAS PubMed Google Scholar
• Stupp, R. et al. Phase I/IIa trial of cilengitide (EMD121974) and temozolomide with concomitant radiotherapy, followed by temozolomide and cilengitide maintenance therapy in patients (pts) with newly diagnosed glioblastoma (GBM). J. Clin, Oncol., 2007 ASCO Annual Meeting Proceedings. Vol 25, No. 18S Part 1 (June 20 Supplement), 2007: 2000.
• Odekon, L. E., Frewin, M. B., Del Vecchio, P., Saba, T. M. & Gudewicz, P. W. Fibronectin fragments released from phorbol ester-stimulated pulmonary artery endothelial cell monolayers promote neutrophil chemotaxis. Immunology 74, 114–120 (1991).
  CAS PubMed PubMed Central Google Scholar
• Legler, D. F., Wiedle, G., Ross, F. P. & Imhof, B. A. Superactivation of integrin αvβ3 by low antagonist concentrations. J. Cell Sci. 114, 1545–1553 (2001).
  CAS PubMed Google Scholar
• Aznavoorian, S., Stracke, M. L., Krutzsch, H., Schiffmann, E. & Liotta, L. A. Signal transduction for chemotaxis and haptotaxis by matrix molecules in tumor cells. J. Cell Biol. 110, 1427–1438 (1990).
  Article CAS PubMed Google Scholar
• Ebos, J. M. et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15, 232–239 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Paez-Ribes, M. et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15, 220–231 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• MacDonald, T. J. et al. Preferential susceptibility of brain tumors to the antiangiogenic effects of an αv integrin antagonist. Neurosurgery 48, 151–157 (2001).
  CAS PubMed Google Scholar
• Yamada, S. et al. Effect of the angiogenesis inhibitor Cilengitide (EMD 121974) on glioblastoma growth in nude mice. Neurosurgery 59, 1304–1312 (2006).
  Article PubMed Google Scholar
• Gladson, C. L. & Cheresh, D. A. Glioblastoma expression of vitronectin and the αvβ 3 integrin. Adhesion mechanism for transformed glial cells. J. Clin. Invest. 88, 1924–1932 (1991). Reveals a crucial role for integrin αvβ3 and its ligand vitronectin for adhesion and the malignant progression of glioblastoma and may help explain the role of cilengitide in patients with brain cancer.
  Article CAS PubMed PubMed Central Google Scholar
• Park, C. C. et al. β1 integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimensional cultures and in vivo. Cancer Res. 66, 1526–1535 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Bhaskar, V. et al. A function blocking anti-mouse integrin α5β1 antibody inhibits angiogenesis and impedes tumor growth in vivo. J. Transl. Med. 5, 61 (2007).
  Article PubMed PubMed Central CAS Google Scholar
• Bhaskar, V. et al. Volociximab, a chimeric integrin α5β1 antibody, inhibits the growth of VX2 tumors in rabbits. Invest. New Drugs 26, 7–12 (2008).
  Article CAS PubMed Google Scholar
• Ricart, A. D. et al. Volociximab, a chimeric monoclonal antibody that specifically binds α5β1 integrin: a phase I, pharmacokinetic, and biological correlative study. Clin. Cancer Res. 14, 7924–7929 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Kuwada, S. K. Drug evaluation: Volociximab, an angiogenesis-inhibiting chimeric monoclonal antibody. Curr. Opin. Mol. Ther. 9, 92–98 (2007).
  CAS PubMed Google Scholar
• Khalili, P. et al. A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo. Mol. Cancer Ther. 5, 2271–2280 (2006).
  Article CAS PubMed Google Scholar
• Stoeltzing, O. et al. Inhibition of integrin α5β1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice. Int. J. Cancer 104, 496–503 (2003).
  Article CAS PubMed Google Scholar
• Cianfrocca, M. E. et al. Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2), a beta integrin antagonist, in patients with solid tumours. Br. J. Cancer 94, 1621–1626 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Harms, J. F. et al. A small molecule antagonist of the αvβ3 integrin suppresses MDA-MB-435 skeletal metastasis. Clin. Exp. Metastasis 21, 119–128 (2004).
  Article CAS PubMed Google Scholar
• Reinmuth, N. et al. αvβ3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice. Cancer Res. 63, 2079–2087 (2003).
  CAS PubMed Google Scholar
• Zhao, Y. et al. Tumor αvβ3 integrin is a therapeutic target for breast cancer bone metastases. Cancer Res. 67, 5821–5830 (2007).
  Article CAS PubMed Google Scholar
• Shannon, K. E. et al. Anti-metastatic properties of RGD-peptidomimetic agents S137 and S247. Clin. Exp. Metastasis 21, 129–138 (2004).
  Article CAS PubMed Google Scholar
• Li, J. et al. Antisense integrin αV and β3 gene therapy suppresses subcutaneously implanted hepatocellular carcinomas. Dig. Liver Dis. 39, 557–565 (2007).
  Article CAS PubMed Google Scholar
• Sipkins, D. A. et al. Detection of tumor angiogenesis in vivo by αVβ3-targeted magnetic resonance imaging. Nature Med. 4, 623–626 (1998).
  Article CAS PubMed Google Scholar
• Cai, W. et al. In vitro and in vivo characterization of 64Cu-labeled Abegrin, a humanized monoclonal antibody against integrin αvβ3. Cancer Res. 66, 9673–9681 (2006).
  Article CAS PubMed Google Scholar
• Winter, P. M. et al. Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel ανβ3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging. Cancer Res. 63, 5838–5843 (2003).
  CAS PubMed Google Scholar
• Leong-Poi, H., Christiansen, J., Klibanov, A. L., Kaul, S. & Lindner, J. R. Noninvasive assessment of angiogenesis by ultrasound and microbubbles targeted to αv-integrins. Circulation 107, 455–460 (2003).
  Article CAS PubMed Google Scholar
• Chen, X. et al. MicroPET imaging of breast cancer αv-integrin expression with 64Cu-labeled dimeric RGD peptides. Mol. Imaging Biol. 6, 350–359 (2004).
  Article PubMed Google Scholar
• Chen, X. et al. MicroPET imaging of brain tumor angiogenesis with 18F-labeled PEGylated RGD peptide. Eur. J. Nucl. Med. Mol. Imaging 31, 1081–1089 (2004).
  Article CAS PubMed Google Scholar
• Zhang, C. et al. Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner. Cancer Res. 67, 1555–1562 (2007).
  Article CAS PubMed Google Scholar
• Bach-Gansmo, T., Bogsrud, T. V. & Skretting, A. Integrin scintimammography using a dedicated breast imaging, solid-state gamma-camera and (99m)Tc-labelled NC100692. Clin. Physiol. Funct. Imaging 28, 235–239 (2008).
  Article PubMed Google Scholar
• Bach-Gansmo, T. et al. Integrin receptor imaging of breast cancer: a proof-of-concept study to evaluate 99mTc-NC100692. J. Nucl. Med. 47, 1434–1439 (2006).
  CAS PubMed Google Scholar
• Haubner, R. et al. Noninvasive visualization of the activated αvβ3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD. PLoS Med. 2, e70 (2005).
  Article PubMed PubMed Central CAS Google Scholar
• Murphy, E. A. et al. Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis. Proc. Natl Acad. Sci. USA 105, 9343–9348 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Wu, L. et al. Distinct FAK-Src activation events promote α5β1 and α4β1 integrin-stimulated neuroblastoma cell motility. Oncogene 27, 1439–1448 (2008).
  Article CAS PubMed Google Scholar
• White, D. P., Caswell, P. T. & Norman, J. C. αvβ3 and α5β1 integrin recycling pathways dictate downstream Rho kinase signaling to regulate persistent cell migration. J. Cell Biol. 177, 515–525 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Fournier, A. K. et al. Rac-dependent cyclin D1 gene expression regulated by cadherin- and integrin-mediated adhesion. J. Cell Sci. 121, 226–233 (2008).
  Article CAS PubMed Google Scholar
• Carrano, A. C. & Pagano, M. Role of the F-box protein Skp2 in adhesion-dependent cell cycle progression. J. Cell Biol. 153, 1381–1390 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Hsu, M. Y. et al. Adenoviral gene transfer of β3 integrin subunit induces conversion from radial to vertical growth phase in primary human melanoma. Am. J. Pathol. 153, 1435–1442 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Hieken, T. J., Ronan, S. G., Farolan, M., Shilkaitis, A. L. & Das Gupta, T. K. Molecular prognostic markers in intermediate-thickness cutaneous malignant melanoma. Cancer 85, 375–382 (1999).
  Article CAS PubMed Google Scholar
• Danen, E. H. et al. Emergence of α5β1 fibronectin- and αvβ3 vitronectin-receptor expression in melanocytic tumour progression. Histopathology 24, 249–256 (1994).
  Article CAS PubMed Google Scholar
• Nip, J., Shibata, H., Loskutoff, D. J., Cheresh, D. A. & Brodt, P. Human melanoma cells derived from lymphatic metastases use integrin αvβ3 to adhere to lymph node vitronectin. J. Clin. Invest. 90, 1406–1413 (1992).
  Article CAS PubMed PubMed Central Google Scholar
• Diaz, L. K. et al. β4 integrin subunit gene expression correlates with tumor size and nuclear grade in early breast cancer. Mod. Pathol. 18, 1165–1175 (2005).
  Article CAS PubMed Google Scholar
• Friedrichs, K. et al. High expression level of α6 integrin in human breast carcinoma is correlated with reduced survival. Cancer Res. 55, 901–906 (1995).
  CAS PubMed Google Scholar
• Slack-Davis, J. K., Atkins, K. A., Harrer, C., Hershey, E. D. & Conaway, M. Vascular cell adhesion molecule-1 is a regulator of ovarian cancer peritoneal metastasis. Cancer Res. 69, 1469–1476 (2009).
  Article CAS PubMed Google Scholar
• Landen, C. N. et al. Tumor-selective response to antibody-mediated targeting of αvβ3 integrin in ovarian cancer. Neoplasia 10, 1259–1267 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Hazelbag, S. et al. Overexpression of the αvβ6 integrin in cervical squamous cell carcinoma is a prognostic factor for decreased survival. J. Pathol. 212, 316–324 (2007).
  Article CAS PubMed Google Scholar
• Bello, L. et al. αvβ3 and αvβ5 integrin expression in glioma periphery. Neurosurgery 49, 380–389 (2001).
  CAS PubMed Google Scholar
• Adachi, M. et al. Significance of integrin α5 gene expression as a prognostic factor in node-negative non-small cell lung cancer. Clin. Cancer Res. 6, 96–101 (2000).
  CAS PubMed Google Scholar
• Winter, P. M. et al. Minute dosages of ανβ3-targeted fumagillin nanoparticles impair Vx-2 tumor angiogenesis and development in rabbits. FASEB J. 22, 2758–2767 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Ong, H. T. et al. Intravascularly administered RGD-displaying measles viruses bind to and infect neovessel endothelial cells in vivo. Mol. Ther. 17, 1012–1021 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Cao, L. et al. Enhancement of antitumor properties of TRAIL by targeted delivery to the tumor neovasculature. Mol. Cancer Ther. 7, 851–861 (2008).
  Article CAS PubMed Google Scholar
• Pramanik, D. et al. Lipopeptide with a RGDK tetrapeptide sequence can selectively target genes to proangiogenic α5β1 integrin receptor and mouse tumor vasculature. J. Med. Chem. 51, 7298–7302 (2008).
  Article CAS PubMed Google Scholar
• Dijkgraaf, I. et al. αvβ3 integrin-targeting of intraperitoneally growing tumors with a radiolabeled RGD peptide. Int. J. Cancer 120, 605–610 (2007).
  Article CAS PubMed Google Scholar
• Janssen, M. L. et al. Tumor targeting with radiolabeled αvβ3 integrin binding peptides in a nude mouse model. Cancer Res. 62, 6146–6151 (2002).
  CAS PubMed Google Scholar
• Veeravagu, A. et al. Integrin αvβ3-targeted radioimmunotherapy of glioblastoma multiforme. Clin. Cancer Res. 14, 7330–7339 (2008).
  Article CAS PubMed Google Scholar
• Chen, Q. et al. αv integrin-targeted immunoconjugates regress established human tumors in xenograft models. Clin. Cancer Res. 13, 3689–3695 (2007).
  Article CAS PubMed Google Scholar